Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more
Kamada - Asset Resilience Ratio
Kamada (KMDA) has an Asset Resilience Ratio of 21.63% as of March 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2021)
This chart shows how Kamada's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Kamada's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $68.52 Million | 21.63% |
| Total Liquid Assets | $68.52 Million | 21.63% |
Asset Resilience Insights
- Good Liquidity Position: Kamada maintains a healthy 21.63% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Kamada Industry Peers by Asset Resilience Ratio
Compare Kamada's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
|
Ildong Holdings Co Ltd
KO:000230 |
Drug Manufacturers - Specialty & Generic | 1.57% |
Annual Asset Resilience Ratio for Kamada (2009–2021)
The table below shows the annual Asset Resilience Ratio data for Kamada.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 0.00% | $0.00 | $318.67 Million | -- |
| 2020-12-31 | 18.55% | $39.07 Million | $210.66 Million | +0.57pp |
| 2019-12-31 | 17.98% | $31.25 Million | $173.80 Million | -5.55pp |
| 2018-12-31 | 23.53% | $32.50 Million | $138.12 Million | -1.31pp |
| 2017-12-31 | 24.84% | $30.34 Million | $122.11 Million | +6.12pp |
| 2016-12-31 | 18.72% | $18.66 Million | $99.70 Million | -4.08pp |
| 2015-12-31 | 22.80% | $23.26 Million | $101.99 Million | -8.42pp |
| 2014-12-31 | 31.22% | $37.35 Million | $119.62 Million | +20.41pp |
| 2013-12-31 | 10.81% | $15.07 Million | $139.38 Million | -8.19pp |
| 2012-12-31 | 19.00% | $16.93 Million | $89.11 Million | -0.74pp |
| 2011-12-31 | 19.74% | $16.87 Million | $85.45 Million | -2.51pp |
| 2010-12-31 | 22.25% | $20.36 Million | $91.52 Million | +21.41pp |
| 2009-12-31 | 0.84% | $527.72K | $62.91 Million | -- |